1Lusis AJ. Atherosclerosis[J]. Nature, 2000,407: 233.
2AmalJF, Dinh - Xuan AT, PueyoM, et al. Endothelium - de rived nitric oxide and vascular physiology and pathobgy[J]. CeLLMoLLife Sci, 1999,55: 1078 - 1087.
3HolvoetP, Vanhaecke J, Janssens S, et al. Oxidized LDL and Malondial dehyde modified LDL in patients with acute coro- nary syndromes and stable coronary arterydisease [J]. Circulation, 1998,98 (5) : 1487 - 1494.
4Anderson TJ. Assessment and treatment of endothelial dysfunction in humans[J]. J Am CollCardiol, 1999,34(3) : 631 - 638.
5Maseri A. In flammation, atheroselerosis, and ischemin events - exploring the hidden side of the moon[J]. N Engl J Med, 1997,336 : 1014 - 1016.
6Ross R,Glomset JA. Atherosclerosis and the arterical smooth muscle cell:Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis[J]. Science, 1973, 180(93) :1332 - 1339.
2Arbustini E, Grasso M. Morphologlc changes induced by acetylcholine infusion in normal and atheroclerotic coronary arteries[J]. Am J Cardiol,1993,71 (16) :1382-1390.
3Treasure CB, Klein JL. Benificial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease[J]. N Engl J Med,1995,332(8) :481-487.
4Arbustini E,Grasso M.Morphologic changes induced by acetylcholine infusion in normal and atheroclerotic coronary arteries[J].Am J Cardiol,1993,71(16):1382-1390.
5Treasure CB,Klein JL.Benificial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease[J].N Engl J Med,1995,332(8):481-487.
6James K Liao. Beyond lipid lowering: the role of statins in vascular protection[J]. Inter J Cardiol, 2002, 5:5～18.
7Vogel RA. Cholesterol of lowering and endothelial function[J]. Am J Med, 1999, 107:479～87.
8Shepherd J, Cobbe S M, Ford I. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia [J]. N Engl J Med, 1995, 333(20): 1301～1307.
9Rikitake Y, Kawashima S, Takeshita S, et al. Anti-oxidative peoperties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits [J]. Atherosclerosis, 2001, 154:87～96.
10Mariann Harangi, Ildik6 Seres, Zsuzsa Varga, et al. Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage[J]. Europ J Clin Pharmacol, 2004, 60:685～691.
